RPS was incorporated in 2015 to commercialize multiple advanced research projects. Its antifungal product, SaProtectTM, is currently undergoing trials for use in commercial aquaculture operations. The company has designed several DNA/RNAi vaccines, based on its own proprietary platform, to address infectious diseases in fish and animals. Currently RPS is developing a sea lice vaccine for salmon. In addition, RPS develops bioactive compounds for functional foods and is conducting testing of a new herbal dietary supplement for the nutraceutical industry.